Alliance Global Partners Remains a Buy on Pelthos Therapeutics (PTHS)
I'm PortAI, I can summarize articles.
James Molloy from Alliance Global Partners has maintained a Buy rating on Pelthos Therapeutics (PTHS) with a price target of $75.00. The analyst consensus for PTHS is a Strong Buy, with an average price target of $59.80. Molloy focuses on the Healthcare sector and has an average return of -25.0% with a 23.91% success rate on his stock recommendations.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments